Mainz Biomed N.V [MYNZ] stock is trading at $7.89, up 11.28%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The MYNZ shares have gain 12.71% over the last week, with a monthly amount glided 84.35%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Mainz Biomed N.V [NASDAQ: MYNZ] stock has seen the most recent analyst activity on November 25, 2024, when H.C. Wainwright downgraded its rating to a Neutral. Previously, Cantor Fitzgerald downgraded its rating to Neutral on November 21, 2023. On June 21, 2022, H.C. Wainwright initiated with a Buy rating and assigned a price target of $25 on the stock.
Mainz Biomed N.V [MYNZ] stock has fluctuated between $3.65 and $45.60 over the past year. Mainz Biomed N.V [NASDAQ: MYNZ] shares were valued at $7.89 at the most recent close of the market.
Analyzing the MYNZ fundamentals
Gross Profit Margin for this corporation currently stands at 0.57% with Operating Profit Margin at -29.75%, Pretax Profit Margin comes in at -29.36%, and Net Profit Margin reading is -29.36%. To continue investigating profitability, this company’s Return on Assets is posted at -1.71, Equity is -3.03 and Total Capital is -4.32. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 2.28.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 7.23 points at the first support level, and at 6.56 for the second support level. However, for the 1st resistance point, the stock is sitting at 8.36, and for the 2nd resistance point, it is at 8.83.
Ratios To Look Out For
For context, Mainz Biomed N.V’s Current Ratio is 0.97. Also, the Quick Ratio is 0.91, while the Cash Ratio stands at 0.77. Considering the valuation of this stock, the price to sales ratio is 19.47, the price to book ratio is 1.28.
